Lates News

date
19/08/2025
Due to lower-than-expected mid-term trial data for Viking Therapeutics' (VKTX.US) experimental oral weight loss drug, the stock plummeted nearly 34% in pre-market trading on Tuesday. Viking stated in a release that their oral GLP-1R/GIPR dual agonist VK2735 can help patients lose up to 12.2% of their weight. However, about 28% of patients dropped out of the trial in just three months, diminishing confidence in the drug's ability to compete with drugs from Eli Lilly (LLY.US) and Novo Nordisk (NVO.US). Mizuho Securities analyst Jared Holz noted, "It's worth noting the high dropout rate of patients within the 13-week period."
Latest
See all latestmore